The research, led by Jin Li and Mei-Fang Xu, with corresponding author Pei-Sen Yao of Fujian Medical University, employed a method called Mendelian randomization. Rather than following patients over time and comparing those who take diuretics with those who do not, an approach vulnerable to confounding and reverse causation, the team exploited natural genetic variation. Because genetic variants are randomly allocated at conception, much like a randomized clinical trial, they can serve as proxies for drug exposure. If people who carry variants that mimic the effects of diuretics show lower rates of bipolar disorder, that strengthens the case for a genuine causal relationship rather than a statistical coincidence.

The technical machinery behind the study drew on two large-scale genome-wide association studies, or GWAS. For the exposure side, the researchers used data on prescription diuretic use from the UK Biobank, a biomedical database containing hundreds of thousands of participants, together with blood pressure summary statistics from the International Consortium of Blood Pressure Genome Wide Association Studies. For the outcome side, they turned to bipolar disorder genetic data from the Psychiatric Genomics Consortium. Single-nucleotide polymorphisms, the individual letter changes in DNA that associate with diuretic use at the genome-wide significance threshold of P less than 5 times 10 to the minus 8, were selected as instrumental variables. These were then pruned for linkage disequilibrium using a stringent r-squared threshold below 0.001 within a 10,000-kilobase window, ensuring that each genetic instrument represented an independent signal rather than a duplicate copy of the same inherited segment.

The headline result was striking in its simplicity. Across the instrumental variable analysis, diuretic use showed a negative association with bipolar disorder risk, with an odds ratio of 0.93 and a 95 percent confidence interval of 0.88 to 0.98, reaching a P value of 6.39 times 10 to the minus 3. In plain terms, genetically proxied diuretic exposure was linked to roughly a 7 percent lower odds of bipolar disorder per unit of exposure. The estimate was calculated using inverse-variance weighting, the workhorse method of two-sample Mendelian randomization, which combines the effects of multiple independent genetic variants into a single causal estimate weighted by their precision. While a 7 percent reduction may sound modest, in the context of a condition that affects tens of millions of people worldwide and often resists existing medications, even small causal signals can point toward meaningful therapeutic avenues.

Crucially, the researchers did not stop at the association. They performed a battery of sensitivity analyses designed to test whether the signal could survive scrutiny. Horizontal pleiotropy, the phenomenon in which genetic variants influence the outcome through pathways unrelated to the exposure of interest, is the chief threat to the validity of any Mendelian randomization study. The team found no evidence of such pleiotropy for the identified associations. They also checked instrument strength using the F statistic, requiring values above 10 to rule out weak-instrument bias, a subtle distortion that arises when genetic proxies explain too little of the variation in the exposure. The genetic instruments passed these quality gates, lending credibility to the core finding.

To move from drug exposure to biological mechanism, the investigators turned to a complementary technique known as summary-data-based Mendelian randomization, or SMR. This method integrates expression quantitative trait loci, the genetic variants that regulate how strongly a gene is expressed, with GWAS data to ask whether a gene’s activity level itself influences disease risk. The analysis flagged two genes connected to diuretic-related biology. The first was ADO, a gene encoding adenosine deaminase, an enzyme involved in purine metabolism and adenosine signaling, a pathway with well-documented roles in neuromodulation. Lower expression of ADO was associated with a higher risk of bipolar disorder, with an odds ratio of 0.72, a 95 percent confidence interval of 0.60 to 0.87, and a P value of 4.71 times 10 to the minus 4.

The colocalization analysis provided the study’s most statistically robust moment. Colocalization asks whether the same causal variant drives both a gene’s expression and the disease association in a given genomic region, or whether two different variants merely happen to sit nearby. The team calculated a posterior probability of hypothesis 4, the scenario in which both traits share a single causal variant, at 92.4 percent for ADO, comfortably above the conventional 0.80 threshold for strong evidence. In other words, the genetic architecture of ADO expression and bipolar disorder risk appear to be genuinely intertwined, making ADO a credible molecular link between diuretic action and psychiatric vulnerability.

The second gene told a more cautionary tale. PRKCA, which encodes protein kinase C alpha, an enzyme central to intracellular signaling and previously implicated in mood regulation, showed the opposite direction of effect: higher expression was linked to greater bipolar risk, with an odds ratio of 1.21, a 95 percent confidence interval of 1.07 to 1.38, and a P value of 3.27 times 10 to the minus 3. However, the posterior probability of a shared causal variant between PRKCA expression and bipolar disorder was only 6.36 percent, far below the threshold for confidence. The association with PRKCA therefore remains suggestive rather than established, a reminder that even statistically significant findings in genetic epidemiology can dissolve under closer inspection when linkage cannot be distinguished from causation.

The authors are careful to frame their conclusions as hypothesis-generating rather than practice-changing. In their own words, the findings identify diuretic-related molecular targets associated with bipolar disorder risk and provide potential hypotheses for further investigation of the biological mechanisms and therapeutic relevance of these targets, but they should be considered target-discovery evidence that requires further functional, pharmacological, and clinical validation. This caution is well placed. Mendelian randomization estimates the effect of lifelong, genetically influenced exposure, which may not correspond to the effect of starting a diuretic in midlife. Moreover, the study relied on summary-level data from previously published GWAS and did not involve direct participation of human subjects, meaning no individual patient records were examined. Clinical trials would be needed before any diuretic could be considered for psychiatric use.

Nevertheless, the study exemplifies a growing strategy in drug repurposing, the search for new uses for old medicines. Repurposed drugs arrive with known safety profiles, established manufacturing, and in some cases decades of real-world evidence, dramatically shortening the path from discovery to patients. The work, supported by the Fujian Provincial Science and Technology Innovation Joint Fund and conducted under UK Biobank application number 94695, also highlights the power of publicly available genetic datasets to generate psychiatric leads from the comfort of the computational laboratory. Whether diuretics ultimately earn a place in the bipolar disorder treatment arsenal remains an open question, but the study has supplied something psychiatry desperately needs: concrete, genetically grounded molecular targets, chief among them ADO, around which future experiments, drug screens, and perhaps one day clinical trials can be built.

Subject of Research: Genetic evidence for repurposing diuretics as a potential therapy for bipolar disorder

Article Title: Repurposing diuretics for bipolar disorder: a Mendelian randomization study

Article References: Li, J., Xu, M.-F., Ye, R.-T., Wang, S.-H., & Yao, P.-S. (2026). Repurposing diuretics for bipolar disorder: a Mendelian randomization study. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08581-1

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08581-1

Keywords: bipolar disorder, diuretics, Mendelian randomization, drug repurposing, genetics, GWAS, UK Biobank, ADO gene, PRKCA, Psychiatry, colocalization, molecular targets

Myxomatous mitral valve disease is a degenerative condition in which the mitral valve, the one-way gate between the left atrium and left ventricle of the heart, gradually thickens and deforms. The disease involves profound changes in the cellular makeup and extracellular matrix of the valve tissue, particularly in collagen content and alignment. The spongy middle layer of the valve leaflets expands as proteoglycans accumulate, while activated myofibroblasts break down collagen and elastin through increased release of proteolytic enzymes. The result is a malformed valve apparatus that no longer seals properly, allowing blood to leak backward from the left ventricle into the left atrium with every heartbeat. This leakage, known as mitral regurgitation, drives progressive enlargement of the left-sided heart chambers and eventually culminates in congestive heart failure.

A key anatomical feature in this disease is the coaptation gap, the space between the anterior and posterior leaflets of the mitral valve when they should be meeting to form a seal. The larger this gap, the greater the volume of blood that escapes backward with each contraction. In most patients, once heart failure sets in, the only options are medications to manage the symptoms and, in some specialized centers, surgical valve repair. Without surgery, the valve condition deteriorates in nearly all cases, and as diuretic resistance develops and the ceiling effect of these drugs is reached, patients progress to Stage D of the American College of Veterinary Internal Medicine classification, a refractory state defined in dogs by a total daily furosemide dose of 8 milligrams per kilogram or an equivalent torsemide dosage. At that point, the prognosis is grim.

The three dogs in the report, all Maltese, arrived at the hospital with classic signs of left heart failure: coughing, breathing difficulties, and elevated sleeping respiratory rates. All three underwent echocardiography performed by a single experienced operator using the same ultrasound system, with standardized imaging views and measurement protocols applied consistently. Each dog showed severe mitral regurgitation, partial rupture of the chordae tendineae, the tendon-like strands that anchor the valve leaflets, and significant enlargement of the left atrium and left ventricle. Standard heart failure treatment was initiated, including furosemide, an angiotensin-converting enzyme inhibitor, pimobendan, and spironolactone, and in all cases the clinical symptoms improved. What happened next was anything but standard.

The first case, a 14-year-old spayed female Maltese, presented with a sleeping respiratory rate exceeding 35 breaths per minute for more than three consecutive days. Her initial echocardiogram revealed an anterior mitral valve leaflet thickened to 4.63 millimeters, a coaptation gap of 4.18 millimeters, and a regurgitant volume of 98.8 milliliters with a regurgitant fraction of 95.4 percent, figures consistent with catastrophic valve leakage. Her furosemide dose was eventually escalated to 8 milligrams per kilogram per day along with torsemide at 0.4 milligrams per kilogram per day. Yet 26 months after her initial visit, radiographs showed her heart had shrunk, with the vertebral heart size falling from 12.8 to 11.6 and the vertebral left atrial size dropping from 3.2 to 2.4. The valve had actually thickened further to 9.55 millimeters, but the coaptation gap had vanished, becoming too small to measure. Her regurgitant volume plummeted to 5.67 milliliters and the regurgitant fraction to 34.5 percent. She has now been managed with pimobendan alone for six months, free of diuretics.

The second case, a 9-year-old castrated male Maltese, arrived with dyspnoea and coughing and required intravenous furosemide and oxygen supplementation to stabilize. His initial echocardiogram showed a coaptation gap of 3.61 millimeters, a regurgitant fraction of 96 percent, and a regurgitant jet occupying 88.5 percent of the left atrial area. Twenty-eight months later, his vertebral heart size had decreased from 11.3 to 10.0, the coaptation gap was no longer measurable, and the jet area ratio had collapsed to 11.1 percent, indicating mild regurgitation. His regurgitant volume fell from 28.33 to 3.46 milliliters. He has been maintained on pimobendan alone for 22 months. The third case, a 12-year-old castrated male Maltese, followed a similar arc over 12 months: his regurgitant fraction dropped from 96.36 to 62.61 percent, his left atrial-to-aortic ratio improved from 2.53 to 1.55, and he has been diuretic-free for nine months.

The quantitative echocardiographic methods used to track these changes were rigorous. Regurgitant volume and regurgitant fraction were calculated from four key measurements: the diameter of the aortic valve during systole, the velocity-time integral of aortic outflow, the diameter at the tips of the mitral leaflets during early diastole, and the velocity-time integrals of the E and A waves of mitral inflow. A semi-quantitative measure, the ratio of the regurgitant jet area to the left atrial area, provided an additional cross-check. In all three dogs, every parameter moved in the direction of improvement, even as the valves themselves continued to degenerate and thicken, a paradoxical combination that has never before been documented at this stage of the disease.

The authors propose that the phenomenon may parallel rare human cases in which severe regurgitation caused by a flail mitral valve improves spontaneously. In human medicine, such improvement has been attributed to mitral valve adaptation, in which the anterior leaflet enlarges to close the coaptation gap, promoting reverse ventricular remodelling without surgery. This process has been suggested to involve the reactivation of embryonic developmental pathways, including endothelial-to-mesenchymal transformation, leading to increased leaflet area and thickness that restore coaptation and reduce leakage. Whether a similar mechanism operated in these dogs remains unknown, and the authors caution that the exact structural changes underlying their observations are unclear. The report also acknowledges an important limitation: the contribution of pimobendan, a drug known to improve haemodynamics, cannot be fully excluded, although there is currently limited evidence that it can induce marked and sustained reductions in regurgitation severity and cardiac remodelling in advanced disease.

The prognostic implications are striking. Using the Mitral INsufficiency Echocardiographic score, a tool for predicting severity and survival in dogs with severe mitral regurgitation, the expected median survival duration for these three dogs was approximately 623 days. Instead, all three survived well beyond that window, remaining alive without dyspnoea, coughing, or syncope months to years after discontinuing diuretics. The authors suggest the cases point to three remarkable possibilities: spontaneous healing of valve function despite ongoing degeneration, reversal of cardiac remodelling without surgery, and long-term survival that current prognostic models fail to predict. Recent evidence from surgical studies has shown that restoring coaptation length can reverse remodelling even in late-stage disease, but these dogs achieved similar outcomes naturally, as if they had undergone repair without ever seeing an operating theatre.

For now, the authors emphasize caution. The prognosis for myxomatous mitral valve disease accompanied by chordae tendineae rupture remains poor, and such spontaneous improvements are exceedingly rare. But the report opens a genuinely new avenue of inquiry: if the valve apparatus can, in some patients, remodel itself to close the leak, identifying the biological signals that drive this adaptation could transform how veterinarians and perhaps even human cardiologists approach degenerative valve disease. Further research is needed to uncover the mechanisms behind this phenomenon and to find markers that might predict which patients will experience such favourable outcomes. In the meantime, three elderly Maltese dogs are breathing easily on a single daily medication, living proof that even the most predictable of diseases can occasionally surprise the experts who study it.

Subject of Research: Spontaneous reduction of mitral regurgitation in dogs with severe myxomatous mitral valve disease

Article Title: Spontaneous Reduction in Mitral Valve Regurgitation in Three Dogs With Severe Myxomatous Mitral Valve Disease: An Unusual Case Report

Article References: Nam, H.-S., & Oh, Y. (2026). Spontaneous Reduction in Mitral Valve Regurgitation in Three Dogs With Severe Myxomatous Mitral Valve Disease: An Unusual Case Report. Veterinary Medicine and Science, 12(6), Article e71155. https://doi.org/10.1002/vms3.71155

Image Credits: AI Generated

DOI: 10.1002/vms3.71155

Keywords: myxomatous mitral valve disease, mitral regurgitation, dogs, veterinary cardiology, echocardiography, coaptation gap, chordae tendineae rupture, heart failure, pimobendan, diuretics, reverse remodelling, case report

The central finding across all three investigations is that well-constructed clinical decision support tools can nudge clinicians toward evidence-based decisions without slowing them down. In the emergency department study, the research team evaluated a tool designed to help clinicians select an appropriate dose of an intravenous loop diuretic for patients arriving with acute decompensated heart failure. This class of medication removes excess fluid that accumulates when the failing heart cannot maintain adequate circulation, allowing the heart to pump more effectively and relieving the profound shortness of breath that drives these patients to seek emergency care in the first place. Clinical guidelines recommend that patients with acute decompensated heart failure receive at least twice the dose of diuretics they take at home when they arrive in the emergency department, a bolus strategy intended to achieve rapid decongestion. In practice, however, the relentless demands of a busy emergency department make it difficult for clinicians to quickly review home medication lists and adjust diuretic therapy accordingly, and recommended dosing is frequently missed.

To address this gap, the University of Michigan team implemented an interruptive alert within the electronic health record that fired when a patient showed signs of fluid overload or kidney dysfunction, prompting the treating clinician to consider guideline-recommended diuretic dosing. The alert was triggered in 223 patient encounters at the U-M Health Emergency Department. In nearly three-quarters of those cases, clinicians followed the recommended diuretic dosing after the alert appeared. Critically, the tool accomplished this without creating the kind of delay that often undermines the adoption of decision support systems: the median time from arrival at the emergency department to diuretic administration was roughly two hours in both groups, meaning the alert influenced the content of the treatment decision rather than its timing.

The researchers were careful to note the limits of what the study demonstrated. The investigation did not assess whether following the digital alerts improved downstream patient outcomes such as the amount of fluid removed or the length of hospital stay. Even so, the results establish something foundational for the field: the tools are easily used in a real clinical setting and measurably affect treatment decisions. As Sarah Adie, Pharm.D., a clinical cardiology pharmacy specialist at U-M Health and an author on all three studies, explained, this is a critical first step toward broad clinical adoption in settings that treat critically ill cardiac patients. Demonstrating feasibility and behavioral impact in a live emergency department environment is a prerequisite for the larger outcome trials that would justify deployment across many institutions.

The second study shifted the setting to the intensive care unit and examined sedation practices in more than 1,600 patients receiving mechanical ventilation in the cardiac and medical intensive care units. Deep sedation is common in intensive care, but leading cardiac and critical care society guidelines favor limiting its use, because prolonged heavy sedation may contribute to worse outcomes, including prolonged ventilator dependence and longer recovery. Changing sedation practice, however, is notoriously difficult, since it requires coordinated action from both physicians and nurses at the bedside, often under time pressure. The research team introduced an electronic health record-based intervention that encouraged the care team to use lighter sedation, surfacing the recommendation at the moment sedative decisions were being made.

The results were striking. After implementation, the average amount of time patients spent deeply sedated during the first 48 hours after intubation dropped in the cardiac intensive care unit from 16.8 hours to 12.4 hours, a reduction of more than four hours per patient. Nurses also reduced the continuous dose of commonly used sedatives, including fentanyl, propofol, midazolam and dexmedetomidine, in 23 percent of cases when the electronic health record generated an alert. These figures suggest that a well-timed digital prompt can shift entrenched practice patterns in an environment where clinicians are managing multiple simultaneous demands. As Anna Barker, M.D., Ph.D., a pulmonologist at University of Michigan Health and senior author of the light sedation paper, emphasized, the alerts are not designed to replace clinical judgment; rather, they are a tool delivered at high-pressure moments to assist clinicians with evidence-based guidance.

The third study tackled one of the most treacherous diagnostic challenges in cardiology: normotensive cardiogenic shock. This condition occurs when the heart cannot pump enough blood to the organs even though the patient’s blood pressure remains normal. Because cardiogenic shock is classically associated with low blood pressure, clinicians may fail to recognize that a normotensive patient is already in shock, and delays in diagnosis can be life threatening. The researchers implemented an electronic health record alert that identified patients displaying additional physiological signs of normotensive cardiogenic shock, such as subtle markers of hypoperfusion that might otherwise be overlooked, and facilitated direct communication with the shock team in the cardiac intensive care unit.

Clinicians engaged with the alert in 14 percent of cases, and those engagements were linked with higher rates of cardiac intensive care unit consultation within 12 hours. While the engagement rate may appear modest, the study illustrates a different design philosophy from the diuretic and sedation alerts: rather than prompting a medication decision, this alert functioned as a recognition and escalation tool, bridging the gap between a bedside clinician who may not suspect shock and a specialized team equipped to deploy advanced therapies. In conditions where early specialist involvement changes the trajectory of illness, even a low-frequency, high-value alert can be clinically meaningful.

Taken together, the three studies map how targeted electronic health record alerts can assist clinicians across the continuum of critical cardiac care, from the first hours in the emergency department through intensive care management. The design of each intervention differed according to the clinical problem. In the emergency department, the tool offered patient-specific recommendations at the moment the diuretic order was placed, embedding the guideline directly into the ordering workflow. In the two intensive care unit studies, alerts prompted clinicians to limit deep sedation or to escalate suspected shock cases to specialized critical care teams. In each case, the intervention respected the existing workflow rather than adding parallel tasks, which the researchers identify as a key principle: these clinical decision support tools are most useful when they help clinicians make the right decision in the moment, rather than adding more noise to already busy workflows, as Scott Ketcham, M.D., a cardiologist at the University of Michigan Health Frankel Cardiovascular Center and an author on all three studies, observed.

The researchers describe the work as proof of concept, and they are explicit that more must be done to ensure electronic alerts are beneficial without disrupting clinical workflow. Alert fatigue remains one of the most persistent problems in health information technology, as clinicians bombarded with low-value notifications learn to dismiss them reflexively, undermining even genuinely useful tools. The Michigan studies suggest a path forward: alerts that are triggered by specific clinical signals, deliver a single actionable recommendation, and arrive at the exact moment a decision is being made. The next step, according to Ketcham, is to evaluate these interventions across multiple health systems to better understand their impact on patient outcomes and determine how they can help improve the care of critically ill cardiac patients nationwide. If those multi-center evaluations confirm what these early studies hint at, the electronic health record, long criticized as a source of friction, may earn a new role as an active partner in the care of the sickest patients with heart disease.

Subject of Research: Electronic health record clinical decision support alerts for critically ill cardiac patients

Article Title: Digital alerts support timely treatment decisions of critically ill cardiac patients

Article References: Digital alerts support timely treatment decisions of critically ill cardiac patients. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: electronic health records, clinical decision support, acute decompensated heart failure, diuretics, cardiac intensive care, sedation, cardiogenic shock, emergency department, ventilators, alert fatigue, Michigan Medicine, patient outcomes

The infant, who had been receiving chlorothiazide for the respiratory complications characteristic of bronchopulmonary dysplasia, presented at five months of chronological age, equivalent to two months of corrected age, with petechiae and mucosal bleeding. When bloodwork came back, the platelet count had plummeted to 7 × 10⁹ per liter, a level so low that spontaneous bleeding becomes a serious clinical concern. Normal platelet counts generally range well above 150 × 10⁹ per liter, meaning this infant had lost more than 95 percent of circulating platelets despite having tolerated the drug for over a quarter of a year.

What makes this case medically remarkable is its timing. Drug-induced immune thrombocytopenia, or DITP, is an antibody-mediated adverse effect that typically announces itself within days to weeks of drug exposure. The immune system, in susceptible individuals, generates antibodies that recognize a drug bound to platelet surfaces, marking the platelets for destruction by the spleen. In this infant, however, the reaction emerged only after more than three months of continuous therapy, a delayed onset that could easily have misled clinicians toward other diagnoses and delayed the correct intervention.

The diagnostic workup was exhaustive. Because isolated thrombocytopenia in an infant carries a long differential diagnosis, the clinical team systematically excluded infectious causes, including congenital and acquired viral infections, as well as malignant and consumptive processes such as disseminated intravascular coagulation. Neonatal alloimmune thrombocytopenia, in which maternal antibodies cross the placenta and attack fetal platelets, was also considered and ruled out. A bone marrow examination showed no evidence of leukemia or aplastic failure; instead, the findings were compatible with peripheral platelet destruction, the hallmark of an immune-mediated process occurring in the bloodstream rather than a failure of platelet production in the marrow.

The definitive answer came from a specialized laboratory technique known as monoclonal antibody immobilization of platelet antigens, or MAIPA. This assay can detect antibodies that bind to platelet glycoproteins only in the presence of a specific drug. In this case, the testing confirmed chlorothiazide-dependent antibodies directed against glycoprotein IIb/IIIa, the integrin receptor that platelets use to aggregate and form clots. The demonstration of drug-dependent anti-GPIIb/IIIa antibodies transformed the case from a diagnostic puzzle into a clear example of chlorothiazide-induced immune thrombocytopenia, an entity almost never reported in infants receiving prolonged diuretic therapy.

Treatment followed the established logic of immune-mediated platelet destruction. The offending drug was discontinued immediately, and intravenous immunoglobulin, or IVIG, was administered. IVIG works through several mechanisms, including saturating the Fc receptors on macrophages in the spleen so that antibody-coated platelets escape destruction. The response was rapid and decisive: the infant’s platelet count returned to normal within one week, confirming that removing the drug and damping the immune destruction was sufficient to reverse the condition without further intervention.

Long-term follow-up added reassuring context to an alarming episode. At six months of corrected age, the child maintained sustained normal platelet counts, showed appropriate growth at 7.8 kilograms, placing the infant at the 30th percentile, and demonstrated normal neurodevelopment on Ages and Stages Questionnaire screening. No further bleeding or infectious complications were documented. The complete recovery underscores that, once the trigger is identified and removed, drug-induced immune thrombocytopenia in infancy can resolve fully without lasting consequences.

The clinical lesson embedded in this case is one of vigilance rather than alarm. Chlorothiazide remains a cornerstone of therapy for infants with bronchopulmonary dysplasia, where it helps reduce pulmonary edema and improve respiratory mechanics, and serious adverse reactions remain exceedingly rare. But the authors argue that the rarity of the reaction is precisely why it can be overlooked. When a preterm infant on prolonged thiazide therapy presents with isolated thrombocytopenia, medication-related causes deserve a place near the top of the differential, even when the drug has been tolerated for months without incident.

The case also highlights the value of modern immunological diagnostics in pediatrics. Without MAIPA testing, the connection between chlorothiazide and the platelet destruction would have remained presumptive, resting on temporal association and the exclusion of alternatives. By confirming drug-dependent antibodies against a specific platelet glycoprotein, the clinicians converted suspicion into proof, a distinction that matters both for the individual patient, who can now avoid the drug permanently, and for the broader medical record, where confirmed cases inform future prescribing decisions and pharmacovigilance databases.

For the community of neonatologists and pediatric hematologists who care for the growing population of surviving extremely preterm infants, the report supports a simple but consequential practice change: routine hematologic monitoring during prolonged thiazide therapy. The infant at the center of this case survived a platelet count that, unrecognized, could have led to catastrophic hemorrhage. That the outcome was instead a full recovery with normal development reflects both the resilience of the child and the diagnostic persistence of the clinical team, and it offers a cautionary, ultimately hopeful, data point for a rare reaction hiding inside a very common prescription.

Subject of Research: Chlorothiazide-induced immune thrombocytopenia in a former preterm infant with bronchopulmonary dysplasia

Article Title: Severe, delayed-onset thrombocytopenia after prolonged chlorothiazide use in a former preterm infant with bronchopulmonary dysplasia: a case report

Article References: Adi, M., Ishmuradov, B., Husanov, S., Kuziev, O., & Ashraf, A. (2026). Severe, delayed-onset thrombocytopenia after prolonged chlorothiazide use in a former preterm infant with bronchopulmonary dysplasia: a case report. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07742-1

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07742-1

Keywords: drug-induced immune thrombocytopenia, chlorothiazide, bronchopulmonary dysplasia, preterm infant, thrombocytopenia, diuretics, MAIPA, platelet antibodies, adverse drug reaction, neonatology, IVIG, pediatrics